Who is sponsoring NCT06118398?

NCT06118398 is sponsored by Feng Jinzhou.

What drugs are being tested in NCT06118398?

Interventions in NCT06118398: Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP.

What condition does NCT06118398 study?

NCT06118398 studies Neuromyelitis Optica, Efgartigimod.

Is NCT06118398 still recruiting?

NCT06118398 is currently status unknown. Last updated 7 November 2023.

Last reviewed 2023-11-07 · How we verify

NCT06118398

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

Status unknown Last updated 7 November 2023

What this trial tests

trial testing Intravenous methylprednisolone (IVMP) and Efgartigimod in Neuromyelitis Optica in 24 participants. Status unknown.

Timeline

5 November 2023

Primary endpoint
5 November 2024

5 May 2025

Quick facts

Lead sponsor	Feng Jinzhou
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	24
Start date	5 November 2023
Primary completion	5 November 2024
Estimated completion	5 May 2025

Drugs / interventions tested

Intravenous methylprednisolone (IVMP) and Efgartigimod — full drug profile →
IVMP — full drug profile →

Conditions studied

Neuromyelitis Optica — all drugs for Neuromyelitis Optica →
Efgartigimod — all drugs for Efgartigimod →

Sponsor

Feng Jinzhou — full company profile →

Who can join

18 and older, any sex, with Neuromyelitis Optica or Efgartigimod. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders (NMOSD) patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in the treatment of neuromyelitis optic spectrum disorder.
Yang X, Zhang S, Feng J, Qin X. · · 2025 · cited 1× · PMID 40291752 · DOI 10.1177/17562864251328276
Case report: Efgartigimod treatment in two pediatric patients with chronic inflammatory demyelinating polyneuropathy.
Ran Y, Wu W, Hou C, Zhu H, et al · · 2025 · PMID 41601668 · DOI 10.3389/fimmu.2025.1741057

Verify or expand the search:

Other recruiting trials for Neuromyelitis Optica

Currently open trials in the same condition.

NCT06398158 — Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder · recruiting
NCT05403138 — Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Dis · Phase 2, PHASE3 · active not recruiting

Other Feng Jinzhou trials

Trials by the same sponsor.

NCT06068829 — Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06118398 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Feng Jinzhou
Last refreshed: 7 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06118398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing